Zacks Research Issues Positive Forecast for BHC Earnings

Bausch Health Cos Inc. (NYSE:BHC) – Stock analysts at Zacks Research lifted their Q3 2028 earnings per share estimates for shares of Bausch Health Cos in a research report issued to clients and investors on Tuesday, September 22nd. Zacks Research analyst Team now expects that the company will post earnings of $0.82 per share for the quarter, up from their previous estimate of $0.81. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Bausch Health Cos’ current full-year earnings is $4.35 per share.

A number of other equities research analysts have also commented on the stock. Jefferies Financial Group raised shares of Bausch Health Cos to a “hold” rating in a report on Wednesday, July 22nd. Wall Street Zen upgraded shares of Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings raised shares of Bausch Health Cos from a “sell (d-)” rating to a “sell (d)” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $8.00.

Bausch Health Cos Stock Down 1.8%

Bausch Health Cos stock opened at $5.72 on Friday. The stock has a 50-day simple moving average of $6.10 and a 200 day simple moving average of $5.53. The stock has a market capitalization of $2.14 billion, a price-to-earnings ratio of -1.93 and a beta of 0.37. Bausch Health Cos has a 12-month low of $4.33 and a 12-month high of $8.00.

Bausch Health Cos (NYSE:BHC) last announced its earnings results on Wednesday, July 29th. The company reported $1.26 EPS for the quarter, topping the consensus estimate of $0.96 by $0.30. The company had revenue of $2.83 billion for the quarter, compared to analysts’ expectations of $2.59 billion. Bausch Health Cos had a negative return on equity of 561.95% and a negative net margin of 10.12%.

Institutional Investors Weigh In On Bausch Health Cos

Institutional investors have recently modified their holdings of the business. Roxbury Financial LLC bought a new position in Bausch Health Cos in the third quarter valued at approximately $28,000. Engineers Gate Manager LP lifted its stake in shares of Bausch Health Cos by 149.6% in the 2nd quarter. Engineers Gate Manager LP now owns 249,991 shares of the company’s stock valued at $1,232,000 after purchasing an additional 149,820 shares during the period. Amundi lifted its stake in shares of Bausch Health Cos by 39.9% in the 2nd quarter. Amundi now owns 33,546 shares of the company’s stock valued at $165,000 after purchasing an additional 9,563 shares during the period. Public Employees Retirement System of Ohio bought a new position in shares of Bausch Health Cos in the 2nd quarter worth $2,565,000. Finally, Bank of America Corp DE acquired a new stake in shares of Bausch Health Cos during the second quarter worth $2,816,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Insider Transactions at Bausch Health Cos

In related news, insider Aimee Lenar sold 36,827 shares of Bausch Health Cos stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $7.03, for a total value of $258,893.81. Following the completion of the sale, the insider directly owned 334,853 shares in the company, valued at $2,354,016.59. This trade represents a 9.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 20.67% of the stock is currently owned by corporate insiders.

Bausch Health Cos Company Profile

Bausch Health Companies Inc is a multinational specialty pharmaceutical company headquartered in Laval, Quebec. The company develops, manufactures and markets prescription medicines, branded and generic pharmaceuticals, over-the-counter products and medical devices across a range of therapeutic areas.

Its business includes Salix Pharmaceuticals, which focuses on gastrointestinal treatments; Ortho Dermatologics, which develops prescription therapies for dermatological conditions; and Solta Medical, which provides energy-based medical and aesthetic devices.